SecBot SecBot
6-K ·Filed Jun 2, 2026

IVEVF

Inventiva S.A.
BULLISH
Impact 7/10
Horizonweeks Processed4mo ago SEC0001104659-26-069638
Notable filing: 6-K
Actionable Insight ▲ Bullish

The refinancing deal extends Inventiva's cash runway well into 2028, eliminates the dilutive overhang from EIB warrants, and provides a clear pathway to fund the NATiV3 trial through top-line results. The forced conversion mechanism at 175% and the conversion price premium reflect moderate dilution risk but strong debt restructuring terms. Monitor for NATiV3 trial data, which triggers potential Tranche C drawdown and equity-linked pricing reset. The 94% bull analyst consensus already prices in some of this positive capital structure cleanup.

DirectionBullish
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
IVEVF ▼ -32.65% at T+60d
LONG call ✗ call lost -32.65% · α vs SPY -35.14% · entry $5.33 → $3.59
Entry = T+0 close
Jun 3, 2026
via day close
T+1d
0.00%
call 0.00% · α -0.40%
$5.33
settled 5mo ago
T+5d
0.00%
call 0.00% · α +3.82%
$5.33
settled 5mo ago
T+20d
-32.65%
call -32.65% · α -31.65%
$3.59
settled 4mo ago
T+60d
-32.65%
call -32.65% · α -35.14%
$3.59
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Inventiva S.A. filed a 6-K attaching a Subscription Agreement with funds managed by BlackRock and Claret Capital Partners for a comprehensive debt restructuring deal totaling €130M (expandable to €150M) and a Master Agreement with the EIB to repurchase EIB warrants and prepay the EIB loan. The transaction includes a €120M ADS offering closed yesterday, paving the way to replace existing EIB debt with new secured financing from BlackRock/Claret.

Key Facts

  • Inventiva entered a Subscription Agreement with BlackRock and Claret Capital for €130M (expandable to €150M) in amortized bonds and convertible bonds (OCAs).
  • The deal includes a €35M OCA tranche (9.9% interest) and €40M Tranche B amortized bonds (9.9% cash + 2.1% PIK), plus an optional €55M Tranche C and €20M non-committed tranche conditional on NATiV3 results.
  • A simultaneous $120M ADS offering at $4.40/ADS closed on June 2, 2026, satisfying the condition to raise at least €90M in equity.
  • The company entered a Master Agreement with the EIB to prepay the entire €50M EIB loan and repurchase 2,966,023 EIB warrants for €50M, eliminating the EIB's ant-dilution protections and restructuring remaining warrants.
  • The OCA conversion price is set at a 40% premium to a 30-day VWAP floor, with a forced conversion threshold at 175% of the conversion price.
  • Post-closing, the company must maintain a minimum €30M cash balance, and upon NATiV3 success, an additional €75M cash balance requirement applies.

Financial Impact

€130M new debt facility replacing €50M EIB loan, plus $120M equity raise (€112.8M net) — total new cash estimated at ~€230M.

dilutiondebtcashRunway

Risk Factors

  • Conversion of €35M OCAs into shares at a 40% premium to VWAP could still result in significant dilution if the stock price remains depressed.
  • Failure of the NATiV3 trial (Primary Composite Endpoint) triggers a Termination Event with mandatory prepayment and potential acceleration of all debt.
  • The company posted a $354M net loss and declining revenue in 2025 — the new debt at 9.9%+ interest adds heavy fixed cost for a pre-commercial firm.
  • Tranche C and the €20M non-committed tranche only become available upon NATiV3 success and additional T3 warrant exercise — no guarantee of execution.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001104659-26-069638
Document: tm2616655d1_ex1-2.htm0001104659-26-069638
7 reports for IVEVF
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for IVEVF — sortable, filterable
TypeNow
Jun 9, 2026
19w ago
6-K
NEUTRAL ★ 3/10
$5.33 $3.59▼ −32.65%▼ −39.50%$3.18 (−40.34%)
Jun 3, 2026
20w ago
6-K
NEUTRAL ★ 2/10
$5.33 $3.59▼ −32.65%▼ −35.14%$3.18 (−40.34%)
Jun 2, 2026
20w ago
6-K
BULLISH ★ 7/10
$5.33 $3.59▼ −32.65%▼ −35.14%$3.18 (−40.34%)
May 26, 2026
21w ago
6-K
NEUTRAL ★ 4/10
$5.33 $3.59▼ −32.65%▼ −34.52%$3.18 (−40.34%)
May 22, 2026
22w ago
6-K
BEARISH ★ 6/10
$5.33 $3.59▲ +32.65%▲ +35.37%$3.18 (+40.34%)
Apr 8, 2026
28w ago
20-F
BEARISH ★ 6/10
$5.50 $3.59▲ +34.73%▲ +45.18%$3.18 (+42.18%)
Mar 30, 2026
30w ago
6-K
MIXED ★ 6/10
$5.50 $3.59▼ −34.73%▼ −47.11%$3.18 (−42.18%)
Showing 7 of 7

US Market Status

Market Closed — Opens in 6h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 3, 2026